Bernauer W, Meyer P, Zimmerli W, Daicker B, Ruettimann S
University Eye Hospital, Basel, Switzerland.
Int Ophthalmol. 1992 Nov;16(6):453-7. doi: 10.1007/BF00918436.
Between January 1988 and May 1991 intravenous ganciclovir (GCV) treatment was administered to eight male AIDS-patients with unilateral cytomegalovirus (CMV)-retinitis. Despite of continuous therapy with at least the recommended dose of GCV, three patients developed slowly progressive CMV-retinitis in the fellow eye after 4 to 13 months. The progression could not be stopped by GCV and thus bilateral blindness resulted after 12 to 22 months. The number of CD4-lymphocytes in the blood was reduced in all patients, but particularly in patients with progressive disease. Treatment failure was partly related to the duration of CMV-retinitis and partly to the degree of immunodeficiency. Intravenous treatment with GCV alone can not stop the progression of CMV-retinitis in long-term survivors and in those with advanced immunodeficiency.
1988年1月至1991年5月期间，对8例患有单侧巨细胞病毒（CMV）视网膜炎的男性艾滋病患者进行了静脉注射更昔洛韦（GCV）治疗。尽管持续使用至少推荐剂量的GCV进行治疗，但仍有3例患者在4至13个月后，另一只眼睛出现了缓慢进展的CMV视网膜炎。GCV无法阻止病情进展，因此在12至22个月后导致双侧失明。所有患者血液中的CD4淋巴细胞数量均减少，尤其是病情进展的患者。治疗失败部分与CMV视网膜炎的持续时间有关，部分与免疫缺陷程度有关。仅静脉注射GCV不能阻止长期存活者和免疫缺陷严重者的CMV视网膜炎进展。
